Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangement, Collaborative Arrangements and Research and Development Arrangement - Summarized Financial Information of Equity Method Investee (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]
Current assets		$ 43,333		$ 51,259
Total assets		226,501		197,205
Current liabilities		47,794		42,138
Total liabilities		137,213		101,288
Equity attributable to shareholders		89,014		95,661
Equity attributable to noncontrolling interests		274		256
Total equity		89,288		95,916		$ 77,462		$ 63,473
Equity Method Investment, Summarized Financial Information [Abstract]
Revenues:	[1]	58,496		100,330		81,288
Income from continuing operations		2,172		31,401		22,459
Net income		2,158		31,407		22,025
Income attributable to shareholders		2,119		31,372		21,979
Haleon [Member]
Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]
Current assets			$ 5,876
Noncurrent assets			36,954
Total assets			42,830
Current liabilities			6,117
Noncurrent liabilities			15,744
Total liabilities			21,862
Equity attributable to shareholders			20,719
Equity attributable to noncontrolling interests			249
Total equity			20,968
Equity Method Investment, Summarized Financial Information [Abstract]
Revenues:			13,921
Cost of sales			(5,580)
Gross profit			8,341
Income from continuing operations			1,606
Net income			1,606
Income attributable to shareholders			$ 1,528
Haleon/Consumer Healthcare JV [Member]
Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]
Current assets					$ 5,932
Noncurrent assets					35,204
Total assets					41,137
Current liabilities					5,235
Noncurrent liabilities					17,220
Total liabilities					22,455
Equity attributable to shareholders					18,455
Equity attributable to noncontrolling interests					227
Total equity					18,682
Equity Method Investment, Summarized Financial Information [Abstract]
Revenues:					13,566
Cost of sales					(5,081)
Gross profit					8,486
Income from continuing operations					1,745
Net income					1,745
Income attributable to shareholders					$ 1,675
Consumer Healthcare JV [Member]
Equity Method Investment, Summarized Financial Information [Abstract]
Revenues:							$ 12,836
Cost of sales							(4,755)
Gross profit							8,081
Income from continuing operations							1,614
Net income							1,614
Income attributable to shareholders							$ 1,547
ViiV [Member]
Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]
Current assets		4,237		4,043
Noncurrent assets		3,009		3,014
Total assets		7,245		7,057
Current liabilities		4,085		3,780
Noncurrent liabilities		5,998		5,996
Total liabilities		10,083		9,777
Equity attributable to shareholders		(2,838)		(2,720)
Equity Method Investment, Summarized Financial Information [Abstract]
Revenues:		7,845		6,955		6,380
Cost of sales		(1,060)		(819)		(682)
Gross profit		6,785		6,135		5,698
Income from continuing operations		3,090		3,108		2,040
Net income		3,090		3,108		2,040
Income attributable to shareholders		$ 3,090		$ 3,108		$ 2,040

[1] Earnings = Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s revenues and earnings in 2023 reflect a non-cash revenue reversal of $3.5 billion (see Note 17C). Biopharma’s earnings also include dividend income from our investment in ViiV of $265 million in 2023, $314 million in 2022 and $166 million in 2021.